Incidence of finding residual disease for incidental gallbladder carcinoma

Implications for Re-resection

Timothy M. Pawlik, Ana Luiza Gleisner, Luca Vigano, David A. Kooby, Todd W. Bauer, Andrea Frilling, Reid B. Adams, Charles A. Staley, Eduardo N. Trindade, Richard D. Schulick, Michael A. Choti, Lorenzo Capussotti

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Re-resection for gallbladder carcinoma incidentally discovered after cholecystectomy is routinely advocated. However, the incidence of finding additional disease at the time of re-resection remains poorly defined. Between 1984 and 2006, 115 patients underwent re-resection at six major hepatobiliary centers for gallbladder carcinoma incidentally discovered during cholecystectomy. Data on clinicopathologic factors, operative details, TNM tumor stage, and outcome were collected and analyzed. Data on the incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded. On pathologic analysis, T stage was T1 7.8%, T2 67.0%, and T3 25.2%. The median time from cholecystectomy to re-resection was 52 days. At the time of re-resection, hepatic surgery most often consisted of formal segmentectomy (64.9%). Patients underwent lymphadenectomy (LND) (50.5%) or LND + common bile duct resection (43.3%). The median number of lymph nodes harvested was 3 and did not differ between LND alone (n∈=∈3) vs LND + common duct resection (n∈=∈3) (P∈=∈0.35). Pathology from the re-resection specimen noted residual/additional disease in 46.4% of patients. Of those patients staged as T1, T2, or T3, 0, 10.4, and 36.4%, respectively, had residual disease within the liver (P∈=∈0.01). T stage was also associated with the risk of metastasis to locoregional lymph nodes (lymph node metastasis: T1 12.5%; T2 31.3%, T3 45.5%; P∈=∈0.04). Cystic duct margin status predicted residual disease in the common bile duct (negative cystic duct, 4.3% vs positive cystic duct, 42.1%) (P∈=∈0.01). Aggressive re-resection for incidental gallbladder carcinoma is warranted as the majority of patients have residual disease. Although common duct resection does not yield a greater lymph node count, it should be performed at the time of re-resection for patients with positive cystic duct margins because over one-third will have residual disease in the common bile duct.

Original languageEnglish (US)
Pages (from-to)1478-1487
Number of pages10
JournalJournal of Gastrointestinal Surgery
Volume11
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Gallbladder Diseases
Cystic Duct
Carcinoma
Common Bile Duct Diseases
Incidence
Cholecystectomy
Gallbladder
Lymph Nodes
Neoplasm Metastasis
Segmental Mastectomy
Common Bile Duct
Lymph Node Excision
Liver Diseases
Pathology
Liver
Neoplasms

Keywords

  • Common bile duct
  • Gallbladder carcinoma
  • Incidental
  • Resection
  • Residual disease

ASJC Scopus subject areas

  • Surgery

Cite this

Pawlik, T. M., Gleisner, A. L., Vigano, L., Kooby, D. A., Bauer, T. W., Frilling, A., ... Capussotti, L. (2007). Incidence of finding residual disease for incidental gallbladder carcinoma: Implications for Re-resection. Journal of Gastrointestinal Surgery, 11(11), 1478-1487. https://doi.org/10.1007/s11605-007-0309-6

Incidence of finding residual disease for incidental gallbladder carcinoma : Implications for Re-resection. / Pawlik, Timothy M.; Gleisner, Ana Luiza; Vigano, Luca; Kooby, David A.; Bauer, Todd W.; Frilling, Andrea; Adams, Reid B.; Staley, Charles A.; Trindade, Eduardo N.; Schulick, Richard D.; Choti, Michael A.; Capussotti, Lorenzo.

In: Journal of Gastrointestinal Surgery, Vol. 11, No. 11, 11.2007, p. 1478-1487.

Research output: Contribution to journalArticle

Pawlik, TM, Gleisner, AL, Vigano, L, Kooby, DA, Bauer, TW, Frilling, A, Adams, RB, Staley, CA, Trindade, EN, Schulick, RD, Choti, MA & Capussotti, L 2007, 'Incidence of finding residual disease for incidental gallbladder carcinoma: Implications for Re-resection', Journal of Gastrointestinal Surgery, vol. 11, no. 11, pp. 1478-1487. https://doi.org/10.1007/s11605-007-0309-6
Pawlik, Timothy M. ; Gleisner, Ana Luiza ; Vigano, Luca ; Kooby, David A. ; Bauer, Todd W. ; Frilling, Andrea ; Adams, Reid B. ; Staley, Charles A. ; Trindade, Eduardo N. ; Schulick, Richard D. ; Choti, Michael A. ; Capussotti, Lorenzo. / Incidence of finding residual disease for incidental gallbladder carcinoma : Implications for Re-resection. In: Journal of Gastrointestinal Surgery. 2007 ; Vol. 11, No. 11. pp. 1478-1487.
@article{7f8e0355159e42ae84a4ff783cda45de,
title = "Incidence of finding residual disease for incidental gallbladder carcinoma: Implications for Re-resection",
abstract = "Re-resection for gallbladder carcinoma incidentally discovered after cholecystectomy is routinely advocated. However, the incidence of finding additional disease at the time of re-resection remains poorly defined. Between 1984 and 2006, 115 patients underwent re-resection at six major hepatobiliary centers for gallbladder carcinoma incidentally discovered during cholecystectomy. Data on clinicopathologic factors, operative details, TNM tumor stage, and outcome were collected and analyzed. Data on the incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded. On pathologic analysis, T stage was T1 7.8{\%}, T2 67.0{\%}, and T3 25.2{\%}. The median time from cholecystectomy to re-resection was 52 days. At the time of re-resection, hepatic surgery most often consisted of formal segmentectomy (64.9{\%}). Patients underwent lymphadenectomy (LND) (50.5{\%}) or LND + common bile duct resection (43.3{\%}). The median number of lymph nodes harvested was 3 and did not differ between LND alone (n∈=∈3) vs LND + common duct resection (n∈=∈3) (P∈=∈0.35). Pathology from the re-resection specimen noted residual/additional disease in 46.4{\%} of patients. Of those patients staged as T1, T2, or T3, 0, 10.4, and 36.4{\%}, respectively, had residual disease within the liver (P∈=∈0.01). T stage was also associated with the risk of metastasis to locoregional lymph nodes (lymph node metastasis: T1 12.5{\%}; T2 31.3{\%}, T3 45.5{\%}; P∈=∈0.04). Cystic duct margin status predicted residual disease in the common bile duct (negative cystic duct, 4.3{\%} vs positive cystic duct, 42.1{\%}) (P∈=∈0.01). Aggressive re-resection for incidental gallbladder carcinoma is warranted as the majority of patients have residual disease. Although common duct resection does not yield a greater lymph node count, it should be performed at the time of re-resection for patients with positive cystic duct margins because over one-third will have residual disease in the common bile duct.",
keywords = "Common bile duct, Gallbladder carcinoma, Incidental, Resection, Residual disease",
author = "Pawlik, {Timothy M.} and Gleisner, {Ana Luiza} and Luca Vigano and Kooby, {David A.} and Bauer, {Todd W.} and Andrea Frilling and Adams, {Reid B.} and Staley, {Charles A.} and Trindade, {Eduardo N.} and Schulick, {Richard D.} and Choti, {Michael A.} and Lorenzo Capussotti",
year = "2007",
month = "11",
doi = "10.1007/s11605-007-0309-6",
language = "English (US)",
volume = "11",
pages = "1478--1487",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Incidence of finding residual disease for incidental gallbladder carcinoma

T2 - Implications for Re-resection

AU - Pawlik, Timothy M.

AU - Gleisner, Ana Luiza

AU - Vigano, Luca

AU - Kooby, David A.

AU - Bauer, Todd W.

AU - Frilling, Andrea

AU - Adams, Reid B.

AU - Staley, Charles A.

AU - Trindade, Eduardo N.

AU - Schulick, Richard D.

AU - Choti, Michael A.

AU - Capussotti, Lorenzo

PY - 2007/11

Y1 - 2007/11

N2 - Re-resection for gallbladder carcinoma incidentally discovered after cholecystectomy is routinely advocated. However, the incidence of finding additional disease at the time of re-resection remains poorly defined. Between 1984 and 2006, 115 patients underwent re-resection at six major hepatobiliary centers for gallbladder carcinoma incidentally discovered during cholecystectomy. Data on clinicopathologic factors, operative details, TNM tumor stage, and outcome were collected and analyzed. Data on the incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded. On pathologic analysis, T stage was T1 7.8%, T2 67.0%, and T3 25.2%. The median time from cholecystectomy to re-resection was 52 days. At the time of re-resection, hepatic surgery most often consisted of formal segmentectomy (64.9%). Patients underwent lymphadenectomy (LND) (50.5%) or LND + common bile duct resection (43.3%). The median number of lymph nodes harvested was 3 and did not differ between LND alone (n∈=∈3) vs LND + common duct resection (n∈=∈3) (P∈=∈0.35). Pathology from the re-resection specimen noted residual/additional disease in 46.4% of patients. Of those patients staged as T1, T2, or T3, 0, 10.4, and 36.4%, respectively, had residual disease within the liver (P∈=∈0.01). T stage was also associated with the risk of metastasis to locoregional lymph nodes (lymph node metastasis: T1 12.5%; T2 31.3%, T3 45.5%; P∈=∈0.04). Cystic duct margin status predicted residual disease in the common bile duct (negative cystic duct, 4.3% vs positive cystic duct, 42.1%) (P∈=∈0.01). Aggressive re-resection for incidental gallbladder carcinoma is warranted as the majority of patients have residual disease. Although common duct resection does not yield a greater lymph node count, it should be performed at the time of re-resection for patients with positive cystic duct margins because over one-third will have residual disease in the common bile duct.

AB - Re-resection for gallbladder carcinoma incidentally discovered after cholecystectomy is routinely advocated. However, the incidence of finding additional disease at the time of re-resection remains poorly defined. Between 1984 and 2006, 115 patients underwent re-resection at six major hepatobiliary centers for gallbladder carcinoma incidentally discovered during cholecystectomy. Data on clinicopathologic factors, operative details, TNM tumor stage, and outcome were collected and analyzed. Data on the incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded. On pathologic analysis, T stage was T1 7.8%, T2 67.0%, and T3 25.2%. The median time from cholecystectomy to re-resection was 52 days. At the time of re-resection, hepatic surgery most often consisted of formal segmentectomy (64.9%). Patients underwent lymphadenectomy (LND) (50.5%) or LND + common bile duct resection (43.3%). The median number of lymph nodes harvested was 3 and did not differ between LND alone (n∈=∈3) vs LND + common duct resection (n∈=∈3) (P∈=∈0.35). Pathology from the re-resection specimen noted residual/additional disease in 46.4% of patients. Of those patients staged as T1, T2, or T3, 0, 10.4, and 36.4%, respectively, had residual disease within the liver (P∈=∈0.01). T stage was also associated with the risk of metastasis to locoregional lymph nodes (lymph node metastasis: T1 12.5%; T2 31.3%, T3 45.5%; P∈=∈0.04). Cystic duct margin status predicted residual disease in the common bile duct (negative cystic duct, 4.3% vs positive cystic duct, 42.1%) (P∈=∈0.01). Aggressive re-resection for incidental gallbladder carcinoma is warranted as the majority of patients have residual disease. Although common duct resection does not yield a greater lymph node count, it should be performed at the time of re-resection for patients with positive cystic duct margins because over one-third will have residual disease in the common bile duct.

KW - Common bile duct

KW - Gallbladder carcinoma

KW - Incidental

KW - Resection

KW - Residual disease

UR - http://www.scopus.com/inward/record.url?scp=35148827527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148827527&partnerID=8YFLogxK

U2 - 10.1007/s11605-007-0309-6

DO - 10.1007/s11605-007-0309-6

M3 - Article

VL - 11

SP - 1478

EP - 1487

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -